Intellia Therapeutics Files 8-K
Ticker: NTLA · Form: 8-K · Filed: Sep 25, 2025 · CIK: 1652130
Sentiment: neutral
Topics: disclosure, sec-filing
TL;DR
Intellia Therapeutics filed a routine 8-K on 9/25/25 covering disclosures and exhibits.
AI Summary
On September 25, 2025, Intellia Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures, other events, and financial statements and exhibits. No specific financial figures or material events beyond routine reporting were detailed in the provided excerpt.
Why It Matters
This 8-K filing indicates Intellia Therapeutics is providing updates and disclosures to the SEC, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — The filing appears to be a standard, routine disclosure without any immediate indication of significant new risks or material adverse events.
Key Players & Entities
- Intellia Therapeutics, Inc. (company) — Registrant
- September 25, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Cambridge, Massachusetts (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing for Intellia Therapeutics?
The filing serves as a Current Report pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934, covering Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported is dated September 25, 2025.
Where are Intellia Therapeutics' principal executive offices located?
Intellia Therapeutics' principal executive offices are located at 40 Erie Street, Suite 130, Cambridge, Massachusetts, 02139.
What is Intellia Therapeutics' state of incorporation?
Intellia Therapeutics, Inc. is incorporated in Delaware.
What is the telephone number for Intellia Therapeutics?
The registrant's telephone number, including area code, is (857) 285-6200.
Filing Stats: 1,566 words · 6 min read · ~5 pages · Grade level 15.1 · Accepted 2025-09-25 16:19:06
Key Financial Figures
- $0.0001 — ich registered Common Stock (Par Value $0.0001) NTLA The Nasdaq Global Market Ind
Filing Documents
- d870108d8k.htm (8-K) — 35KB
- d870108dex991.htm (EX-99.1) — 24KB
- g870108g08a77.jpg (GRAPHIC) — 18KB
- 0001193125-25-217484.txt ( ) — 206KB
- ntla-20250925.xsd (EX-101.SCH) — 3KB
- ntla-20250925_lab.xml (EX-101.LAB) — 18KB
- ntla-20250925_pre.xml (EX-101.PRE) — 11KB
- d870108d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K and certain of the materials furnished or filed herewith contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia's beliefs and expectations regarding: the safety, tolerability, efficacy, success and advancement of its clinical programs for nexiguran ziclumeran or "nex-z" (also known as NTLA-2001) for transthyretin ("ATTR") amyloidosis, including the ability to successfully complete its global Phase 3 MAGNITUDE-2 study for hereditary transthyretin ATTR amyloidosis with polyneuropathy ("ATTRv-PN") pursuant to its clinical trial applications and investigational new drug submissions; its expectation to complete enrollment in the MAGNITUDE-2 trial in the first half of 2026; its belief that a single dose of nex-z leads to deep, durable and consistent reductions in serum TTR and that increasingly deep reductions in TTR levels translate to better outcomes for patients; its belief that the MAGNITUDE-2 trial will demonstrate nex-z's potential to halt or reverse disease progression in people living with ATTRv-PN; and its expectation to submit a biologics license application for nex-z for the treatment of ATTRv-PN by 2028. Any forward-looking statements in this current report on Form 8-K are based on management's current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or imp
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Intellia Therapeutics, Inc. (Registrant) Date: September 25, 2025 By: /s/ John M. Leonard Name: John M. Leonard Title: Chief Executive Officer and President